{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037406","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.289125+00:00","generated_at":"2026-06-04T09:48:26.648491+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Annovis Bio raises $3M via registered direct offering of 316,455 shares at $9.48/share","bullets":["Sold 316,455 common shares at $9.48 each for $3.0M gross proceeds under effective Form S-3 shelf registration.","30-day post-closing lock-up restricts new equity issuances, warrant amendments, registration filings, and variable-rate deals.","Closing contingent on NYSE listing of the offered shares; expected promptly after conditions satisfied.","Buyer may sell shares during pre-settlement period and remains unconditionally bound to purchase at closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037406","json":"https://secwatch.observer/filing/0001104659-24-037406.json","markdown":"https://secwatch.observer/filing/0001104659-24-037406.md","text":"https://secwatch.observer/filing/0001104659-24-037406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924037406/0001104659-24-037406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924037406/tm249453d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:48:26.648491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cda93985835e036798fdefaed8c99c82ff067c8c","claim":"Annovis Bio, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2024-03-21).","evidence_excerpt":"On March 21, 2024, Annovis Bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924037406/0001104659-24-037406-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$3,000,000"},{"label":"Effective","value":"2024-03-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}